4D Molecular Therapeutics Inc (NASDAQ: FDMT)’s stock price has dropped by -5.99 in relation to previous closing price of 26.39. Nevertheless, the company has seen a loss of -7.25% in its stock price over the last five trading days. GlobeNewsWire reported 2024-03-04 that EMERYVILLE, Calif., March 04, 2024 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in March. Members of the management team will also be available for one-on-one meetings.
Is It Worth Investing in 4D Molecular Therapeutics Inc (NASDAQ: FDMT) Right Now?
The stock has a 36-month beta value of 2.89. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for FDMT is 44.85M, and at present, short sellers hold a 20.78% of that float. On April 24, 2024, the average trading volume of FDMT was 1.22M shares.
FDMT’s Market Performance
FDMT stock saw a decrease of -7.25% in the past week, with a monthly decline of -26.16% and a quarterly a decrease of 34.40%. The volatility ratio for the week is 6.58%, and the volatility levels for the last 30 days are 6.70% for 4D Molecular Therapeutics Inc (FDMT). The simple moving average for the past 20 days is -12.81% for FDMT’s stock, with a 29.96% simple moving average for the past 200 days.
Analysts’ Opinion of FDMT
Many brokerage firms have already submitted their reports for FDMT stocks, with Barclays repeating the rating for FDMT by listing it as a “Overweight.” The predicted price for FDMT in the upcoming period, according to Barclays is $459 based on the research report published on April 15, 2024 of the current year 2024.
Barclays, on the other hand, stated in their research note that they expect to see FDMT reach a price target of $45. The rating they have provided for FDMT stocks is “Overweight” according to the report published on April 15th, 2024.
Goldman gave a rating of “Buy” to FDMT, setting the target price at $81 in the report published on February 07th of the current year.
FDMT Trading at -13.90% from the 50-Day Moving Average
After a stumble in the market that brought FDMT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.56% of loss for the given period.
Volatility was left at 6.70%, however, over the last 30 days, the volatility rate increased by 6.58%, as shares sank -26.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.34% lower at present.
During the last 5 trading sessions, FDMT fell by -7.25%, which changed the moving average for the period of 200-days by +35.95% in comparison to the 20-day moving average, which settled at $28.01. In addition, 4D Molecular Therapeutics Inc saw 22.46% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FDMT starting from Bizily Scott, who sale 1,750 shares at the price of $25.74 back on Apr 16 ’24. After this action, Bizily Scott now owns 1,737 shares of 4D Molecular Therapeutics Inc, valued at $45,045 using the latest closing price.
Bizily Scott, the Chief Legal Officer of 4D Molecular Therapeutics Inc, sale 8,153 shares at $31.78 during a trade that took place back on Apr 01 ’24, which means that Bizily Scott is holding 1,737 shares at $259,102 based on the most recent closing price.
Stock Fundamentals for FDMT
Current profitability levels for the company are sitting at:
- -5.45 for the present operating margin
- 0.59 for the gross margin
The net margin for 4D Molecular Therapeutics Inc stands at -4.8. The total capital return value is set at -0.35. Equity return is now at value -33.00, with -29.90 for asset returns.
Based on 4D Molecular Therapeutics Inc (FDMT), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -5.17.
Currently, EBITDA for the company is -107.12 million with net debt to EBITDA at 2.13. When we switch over and look at the enterprise to sales, we see a ratio of 49.94. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.07.
Conclusion
To sum up, 4D Molecular Therapeutics Inc (FDMT) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
